Session Abstract – PMWC 2025 Silicon Valley


The PMWC 2024 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.


Confirmed Presenting Companies:

 Speaker Profile

M.D., Senior Vice President, Medical, Castle Biosciences

Biography
Dr. Matthew Goldberg is a board-certified dermatologist and dermatopathologist. Prior to joining Castle, Dr. Goldberg was an Assistant Professor in Dermatology and Pathology at the Icahn School of Medicine at Mount Sinai in New York and retains his affiliation as an Assistant Clinical Professor of Dermatology. Prior to joining the Mount Sinai faculty, he directed Dermatopathology education for the MedStar Georgetown Washington Hospital Center dermatology residency program. Dr. Goldberg has a background in translational melanoma research and received the Dermatology Foundation Dermatopathology Research Career Development Award for research in melanoma epigenetics.


Talk
AI unlocks the clinical utility of spatialomics
Spatialomics provide robust data to interrogate multiple pathways of disease progression simultaneously. Using AI to interpret these pathways can unlock new understanding that has the potential to profoundly improve patient management. This talk will explore how synergies between AI and spatialomics have been validated to predict progression to esophageal cancer in Barretts esophagus patients.


Genomic Profiling Showcase:
Castle Biosciences

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on improving health through innovative tests that guide patient care. Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions.

 Speaker Profile

Ph.D., PHARMD, Deputy CEO &CSO, ALCEDIAG

Biography
Dinah is also co-Director of a public-private laboratory, CNRS 9005, focused on the understanding the molecular basis of complex diseases. Her research field, mainly in neurosciences is dedicated to improve the conditions of patients suffering from mental disorders through the development of innovative therapeutic molecules. Her last focus is the understanding of epigenetic mechanism impact on mood disorders and the development of blood tests to diagnose psychiatric conditions like depression and bipolar disorder. Her goal is to develop and bring to market breakthrough innovations to transform and improve the quality of life of patients


Talk
RNA editing blood biomarkers for bipolar diagnosis
The differential diagnosis of bipolar disorder and MDD is challenging, bipolar patients remain undiagnosed for years. Alcediag has developed blood biomarkers for mood disorder based on RNA editing and artificial intelligence. This panel of biomarkers was tested in two independent cohorts and show high performance in diagnosing bipolar patients.


Genomic Profiling Showcase:
ALCEDIAG

ALCEDIAG is an innovative diagnostic company specializing in the development and commercialization of blood tests, monitoring solutions, and companion diagnostics, primarily for mental health. These offerings are based upon the company’s distinctive expertise in epigenetics, RNA, and Artificial Intelligence, complemented by neurosciences and psychiatry.

 Speaker Profile

Ph.D., Chief Scientific Officer, Precede Biosciences

Biography
Carl is a renowned professional in the field of translational medicine and diagnostics with over 17 years of experience in drug development and technology advancement. In his previous role as the Vice President and Head of Oncology Translational Medicine at AstraZeneca Pharmaceuticals, he led a global team, spearheading biomarker strategy and translational sciences to support oncology drug development. Carls career also includes leadership positions at Novartis Institutes for BioMedical Research and the National Cancer Institute. He has made significant contributions to the field, with over 600 publications to his name and a reputation for mentoring future leaders in the pharmaceutical and biomedical sectors. Driven by a passion for lifelong learning and effective communication, he continues to shape the landscape of healthcare innovation.


Talk
Comprehensive Epigenomic Profiling from Plasma to Inform Therapy Selection
Precede Bio's novel liquid biopsy platform interrogates genome-wide transcriptional biology from 1 mL of plasma through analysis of DNA associated with histone marks of active transcription. This comprehensive multi-analyte epigenomic profiling approach has the potential to investigate the transcriptional status of individual genes and genome-wide biology that is correlated or anti-correlated with targets of interest.


Genomic Profiling Showcase:
Precede Biosciences

Precede Bio is impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform designed to reveal the fundamental biology behind disease at any given moment so that researchers and clinicians can better target medicines to the right patients.

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by NOV. 7TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required